ScholarIQanswers from OpenAlex
Erasmus MC Cancer Institute
InstitutionResearch output, impact & collaborations
Erasmus MC Cancer Institute is a institution indexed in ScholarIQ from OpenAlex.
What is known about Erasmus MC Cancer Institute?
ScholarIQrecord summary
Erasmus MC Cancer Institute is a research organisation in Rotterdam, NL. OpenAlex records 13,355 works and 1,413,391 citations for it. 3,743 researchers list it as their most recent affiliation.
How many works does Erasmus MC Cancer Institute have?
ScholarIQindexed works
Erasmus MC Cancer Institute has 13,355 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Erasmus MC Cancer Institute have?
ScholarIQcitation count
Erasmus MC Cancer Institute has 1,413,391 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Erasmus MC Cancer Institute?
ScholarIQresearcher count
Erasmus MC Cancer Institute has 3,743 researchers in the ScholarIQ index.
What is the average h-index at Erasmus MC Cancer Institute?
ScholarIQavg h-index
Erasmus MC Cancer Institute has an average h-index of 70.4 in OpenAlex.
What is the ROR of Erasmus MC Cancer Institute?
ScholarIQror
The ROR for Erasmus MC Cancer Institute is on the source record.
What is the OpenAlex record for Erasmus MC Cancer Institute?
ScholarIQopenalex
The OpenAlex for Erasmus MC Cancer Institute is on the source record.
Who are the most-cited researchers behind Erasmus MC Cancer Institute?
ScholarIQtop researchers by citations
What are the most-cited papers on Erasmus MC Cancer Institute?
ScholarIQmost cited works
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
Pieter van Hagen, Maarten C.C.M. Hulshof, J. Jan B. van Lanschot, Ewout W. Steyerberg, Mark I. van Berge Henegouwen, Bas P. L. Wijnhoven, Dick J. Richel, Grard A. P. Nieuwenhuijzen, Geke A.P. Hospers, Johannes J. Bonenkamp, Miguel A. Cuesta, R.J.B. Blaisse, Olivier R. Busch, F.J.W. ten Kate, G.J. Creemers, C.J.A. Punt, John Theodorus Plukker, Henk M.W. Verheul, Ernst Jan Spillenaar Bilgen, Herman van Dekken, Maurice J.C. van der Sangen, Tom Rozema, Katharina Biermann, Jannet C. Beukema, Anna H.M. Piet, Caroline M. van Rij, Janny G. Reinders, H.W. Tilanus, Ate van der Gaast
Screening and Prostate-Cancer Mortality in a Randomized European Study
Fritz H. Schröder, Jonas Hugosson, Monique J. Roobol, Teuvo L.J. Tammela, Stefano Ciatto, Vera Nelen, Maciej Kwiatkowski, Marcos Lujan, Hans Lilja, Marco Zappa, Louis Denis, Franz Recker, Antonio Berenguer, Liisa Määttänen, Chris H. Bangma, Gunnar Aus, Arnauld Villers, Xavier Rebillard, Theodorus van der Kwast, B. G. Blijenberg, Sue M. Moss, Harry J. de Koning, Anssi Auvinen
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
Joël Shapiro, J. Jan B. van Lanschot, Maarten C.C.M. Hulshof, Pieter van Hagen, Mark I. van Berge Henegouwen, Bas P. L. Wijnhoven, Hanneke W.M. van Laarhoven, Grard A. P. Nieuwenhuijzen, Geke A.P. Hospers, Johannes J. Bonenkamp, Miguel A. Cuesta, R.J.B. Blaisse, Olivier R. Busch, Fiebo J.W. ten Kate, Geert-Jan Creemers, Cornelis J.A. Punt, John Th. M. Plukker, Henk M.W. Verheul, Ernst Jan Spillenaar Bilgen, Herman van Dekken, Maurice J.C. van der Sangen, Tom Rozema, Katharina Biermann, Jannet C. Beukema, Anna H.M. Piet, Caroline M. van Rij, Janny G. Reinders, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast
Gastroenteropancreatic neuroendocrine tumours
Irvin M. Modlin, Kjell Öberg, Daniel C. Chung, Robert T. Jensen, Wouter W. de Herder, Rajesh V. Thakker, Martyn Caplin, Gianfranco Delle Fave, Gregory Kaltsas, Eric P. Krenning, Steven F. Moss, Ola Nilsson, Guido Rindi, Ramón Salazar, Philippe Ruszniewski, Anders Sundin
Extended Transthoracic Resection Compared with Limited Transhiatal Resection for Adenocarcinoma of the Esophagus
Jan B.F. Hulscher, Johanna W. van Sandick, Angela G. E. M. de Boer, Bas P. L. Wijnhoven, Jan G.P. Tijssen, Paul Fockens, Peep F. M. Stalmeier, Fiebo J.W. ten Kate, Herman van Dekken, H. Obertop, Hugo W. Tilanus, J. Jan B. van Lanschot
How much of the research on Erasmus MC Cancer Institute is open access?
ScholarIQopen access share
58%OPEN ACCESS